34 results
8-K
EX-99.1
CHRS
Coherus BioSciences, Inc.
8 Aug 24
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
4:23pm
charges related to our reduction in workforce. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve …
Impairment of out-license asset and remeasurement of CVR liability, net
Restructuring charges related to reduction in workforce(1)
Amortization
8-K
EX-99.1
CHRS
Coherus BioSciences, Inc.
9 May 24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:17pm
, loss on debt extinguishment and restructuring charges related to our reduction in workforce. These non-GAAP financial measures are not prepared …
Impairment of out-license asset and remeasurement of CVR liability, net
Restructuring charges related to reduction in workforce(1)
Amortization
8-K
EX-99.1
CHRS
Coherus BioSciences, Inc.
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
is expected to result in a reduction in workforce of 30% by the end of 2024, including 35 employees associated with the ophthalmology divestiture … of the reduction of workforce in 2024; and Coherus’ expectations that it will be able to realize value in the future from its pipeline.
Such forward-looking
8-K
EX-99.1
frx n9vch
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
8-K/A
EX-99.1
ejcdf5f
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
8-K
EX-99.1
a6bmue
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
424B3
dqaa020jd lq
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
r8j3ubrjlz g102l
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
7jfs1z 1ojr
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
nal2a adort
16 Jun 23
Business combination disclosure
5:12pm
425
fxjiiguzvwigqu
16 Jun 23
Business combination disclosure
8:08am
425
zhl7survfzskgxd2 5zk
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
pxyeegrp0d31i yb
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-99.1
2jbf ahlfdb5cjl0
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-99.1
euescn0v 8upxar
8 May 23
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
4:16pm